Thus, HLJDD could reduce TEWL by enhancing the epidermal barrier via regulating the expression of FLG, LOR and AQP3 to treat the symptoms of skin lesions in AD-like mice. This evidence concerns the gene LORICRIN and Alzheimer disease.